The Triptan Formulations
- 83 Downloads
The 5-HT1b/1d receptor agonists (the ‘triptans’) are migraine-specific agents that have revolutionised the treatment of migraine. They are usually the drugs of choice to treat a migraine attack in progress. Different triptans are available in various strengths and formulations, including oral tablets, orally disintegrating tablets, nasal sprays and subcutaneous injections. In Europe, sumatriptan is also available as a suppository.
Specific differences among the triptans exist, as evidenced by different pharmacological profiles including half-life, time to peak plasma concentrations, peak plasma concentrations, area under the concentration-time curve, metabolism and drug-drug interaction profiles. How or whether these differences translate to clinical efficacy and tolerability advantages for one agent over another is not well differentiated. However, delivery systems may play an important role in onset of action.
Given that the clinical distinctions among these agents are subtle, identification of the most appropriate triptan for an individual patient requires consideration of the specific characteristics of the patient and knowledge of patient preference, an accurate history of the efficacy of previous acute-care medications and individual features of the drug being considered. The selection of an acute antimigraine drug also depends upon the stratification of the patient’s migraine attack by peak intensity, time to peak intensity, level of associated symptoms such as nausea and vomiting, time to associated symptoms, comorbid diseases and concomitant treatments that might cause drug-drug interactions.
Individual patient response to the triptans seems to be idiosyncratic and possibly genetically determined. Therefore, a set of specific questions can be used to determine whether a currently used triptan is optimally effective, whether the dose needs to be increased or whether another triptan should be tried.
The clinician has in his/her armamentarium an ever-expanding variety of triptans, available in multiple formulations and dosages, which have good safety and tolerability profiles. Continued clinical use will yield familiarity with the various triptans, and it should become possible for the interested physician to match individual patient needs with the specific characteristics of a triptan to optimise therapeutic benefit. Use of the methods outlined in this review in choosing a triptan for an individual patient is probably more likely to lead to migraine relief than making an educated guess as to which triptan is most appropriate.
This study was conducted without financial support. The authors have participated in research and/or lectures sponsored by GlaxoSmithKline, AstraZeneca, Merck Sharpe & Dohme, Pfizer and other major pharmaceutical companies.
- 4.Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8Suppl. 7: 1–96Google Scholar
- 14.Cottrell CK, Gibson JG, Waller SW, et al. The timing of triptan use and its effect on migraine-related disability [abstract]. Cephalalgia 2001; 21: 339–40Google Scholar
- 15.Mansbach H. Sumatriptan: looking back and looking forward. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 183–9Google Scholar
- 16.Dahlõf CGH. Characteristics of different routes of administration. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 80–90Google Scholar
- 18.Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dose strengths. Neurology 1995; 45Suppl. 7: 5–9Google Scholar
- 23.Tepper SJ, Cochran A, Hobbs S, et al. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998: 1: 31–5Google Scholar
- 24.Gõbel H. A placebo-controlled, dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Front Headache Res 1997; 6: 203–6Google Scholar
- 25.Henriksson A. Safety and efficacy of sumatriptan suppositories in the acute treatment of migraine attacks [abstract]. Cephalalgia 1995; 15Suppl. 14: 235Google Scholar
- 29.Tepper SJ. Triptans and the potential for drug interactions. Primary Care Spec Ed 2002; 6: 1–5Google Scholar
- 31.Torres G. Zolmitriptan offers doctors and patient choices for effective treatment of migraine. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 190–8Google Scholar
- 32.Clement EM, Franklin M. Simultaneous measurement of zolmitriptan and its major metabolites N-desmethylzolmitriptan and zolmitriptan N-oxide in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 339–43PubMedCrossRefGoogle Scholar
- 37.Gallagher RM. Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine [abstract]. Cephalalgia 1999; 19: 358Google Scholar
- 41.Dowson AJ, MacGregor EA, Purdy A. Efficacy and safety of zolmitriptan 2.5 mg orally disintegrating tablet for the acute treatment of migraine [abstract]. Cephalalgia 2000; 20: 342Google Scholar
- 44.Dowson AJ, Boes-Hansen S, Farkkila AM. Zolmitriptan nasal spray is fast-acting and highly effective in the acute treatment of migraine [abstract]. Eur J Neurol 2001; 7Suppl. 3: 82Google Scholar
- 45.Abu-Shakra S, Wilmington DE, Yates RA, et al. Distribution and pharmacokinetics of zolmitriptan following administration by nasal spray [abstract]. Neurology 2002; 58: 91–2Google Scholar
- 46.Salonen R. Naratriptan: the gentle triptan. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 228–35Google Scholar
- 49.Goadsby PJ, Asgharnejad M, Winter PD. Twenty-four hour maintenance of headache relief after treatment of migraine with naratriptan tablets: a review of data from controlled clinical trials [abstract]. Headache 1998; 38: 382Google Scholar
- 50.Dahlõf C, Winter P, Whitehouse H, et al. Randomized, double-blind, placebo controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine. Neurology 1997; 48Suppl. 3: 85–6Google Scholar
- 51.Bomhof MK, Legg N, Paz J. Comparison of rizatriptan 10 mg versus naratriptan 2.5 mg in migraine [abstract]. Headache 1999; 39: 344Google Scholar
- 53.Allen C. Rizatriptan: clinical update. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 199–205Google Scholar
- 56.Diener HC, Pascual J, Vega P. Comparison of rizatriptan 10 mg versus zolmitriptan 2.5 mg in migraine [abstract]. Headache 1999; 39: 351Google Scholar
- 57.Saxena PR. Pharmacodynamics of triptans. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 72–9Google Scholar
- 59.Tfelt-Hansen P, Ryan RE. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan: a review of four randomized, double-blind clinical trials. Neurology 2000; 55Suppl. 2: 19–24Google Scholar
- 60.Pascual J. Almotriptan. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 247–52Google Scholar
- 61.Fernandes FJ, Jansat JM, Cabarrocas X, et al. Absolute bioavailability of oral and subcutaneous almotriptan [abstract]. Cephalalgia 1999; 23: 363Google Scholar
- 62.Cabarrocas X, Zayas JM, Suris M. Equivalent efficacy of oral almotriptan, a new 5-HT agonist, compared with sumatriptan 100 mg. Headache 1998; 38: 377–8Google Scholar
- 65.Gupta P, Napier CM, Purdy J, et al. In vitro profile of eletriptan, a new 5-HT1d —like receptor partial agonist [abstract]. Cephalalgia 1996; 16: 368Google Scholar
- 69.Buchan P, Keywood C, Ward C. The pharmacokinetics of frovatriptan (VML 251/SB209509) in male and female subjects [abstract]. Func Neurol 1998; 13: 177Google Scholar
- 70.Keywood C. Frovatriptan: simplifying clinical practice in migraine. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 253–61Google Scholar